Life-threatening asthma during treatment with salmeterol.
Weinberger
Miles
M
Abu-Hasan
Mutasim
M
D000280:Administration, Inhalation; D000293:Adolescent; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000420:Albuterol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000730:Androstadienes / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy*; D001250:Asthma, Exercise-Induced / Q000139:chemically induced*; D001993:Bronchodilator Agents / Q000009:adverse effects* / Q000627:therapeutic use; D019819:Budesonide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004983:Ethanolamines / Q000627:therapeutic use; D000068298:Fluticasone; D006801:Humans; D008297:Male; D000068299:Salmeterol Xinafoate
D000318:Adrenergic beta-Agonists; D000730:Androstadienes; D001993:Bronchodilator Agents; D004983:Ethanolamines; D019819:Budesonide; D000068299:Salmeterol Xinafoate; D000068298:Fluticasone; C009118:pirbuterol; D000420:Albuterol